Desk›Healthcare› Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd
BSE 533573 · NSE APLLTD · ISIN INE901L01018 · Group A · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹823.50
-0.04%
BSE close, 28 August 2026
₹16,186.97 cr
19.7 cr shares · Small cap
₹4,547.84 cr
as published
22.1× · 3.22×
EPS ₹37.33 · BV ₹255.75
6,651.38 / 640.42
₹ cr, as filed
27
9 selected · 33%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -17.5% |
|---|---|
| Against 52-week low | +29.6% |
| Day change | -0.04% |
| Size band | Small cap |
| Index membership | None |
Valuation as published by BSE
| Earnings per share | ₹37.33 |
|---|---|
| Price / earnings | 22.06× |
| Price / book | 3.22× |
| Book value — derived, price ÷ P/B | ₹255.75 |
| Return on equity | 14.58% |
| Operating margin | 19.26% |
| Net margin | 10.54% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 14.60%
- ROE as published
- 14.58%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 1,868.06 | 196.96 | 10.02 | 19.26% | 10.54% |
| Mar-26 · Q | 1,718.74 | 243.07 | 12.37 | 16.01% | 14.14% |
| FY25-26 | 6,651.38 | 640.42 | 32.58 | 15.81% | 9.63% |
Quarter on quarter
- Revenue, quarter on quarter
- +8.7%
- Net profit, quarter on quarter
- -19.0%
- Operating margin, quarter on quarter
- +325 bps
Disclosure profile 27 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Press Release | 3 |
| KMP | 2 |
| Board Outcome | 1 |
| Concall Transcript | 1 |
| Investor Presentation | 1 |
| Results | 1 |
| Selected sub-total | 9 |
| Procedural | |
| Analyst / Investor Meet | 5 |
| Newspaper Publication | 4 |
| General | 3 |
| AGM / EGM | 2 |
| Board Meeting | 1 |
| Compliance Certificate | 1 |
| SAST | 1 |
| Trading Window | 1 |
| Procedural sub-total | 18 |
| Total | 27 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
27 filings · 9 selected · busiest 2026-08-04
Filing rhythm · the twelve most recent
2026-08-202026-10-08
SelectedProcedural
Filings
27 in the window · 26 earlier on record
-
8 October 2026 ·
Newspaper Publication
Please find attached herewith the copy of Newspaper Publication.
Company Update / Newspaper Publication View filing →
-
6 October 2026 ·
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018
Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
-
29 September 2026 ·
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for DSP Trustee Pvt Ltd & Others
Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 View filing →
-
28 September 2026 ·
Closure of Trading Window
Please find enclosed Intimation of Trading Window Closure.
Insider Trading / SAST / Closure of Trading Window View filing →
-
18 September 2026 ·
Analyst / Investor Meet - Intimation
Please find enclosed Intimation of One to One Investor Meet.
Company Update / Analyst / Investor Meet View filing →
-
16 September 2026 ·
Update On USFDA Inspection Conducted During 3Rd March, 2025 To 7Th March, 2025 At Bioequivalence Facility Located At Vadodara, Gujarat.
Update on USFDA inspection conducted during 3rd March, 2025 to 7th March, 2025 at Bioequivalence Facility located at Vadodara, Gujarat.
Company Update / General View filing →
-
11 September 2026 ·
Intimation Regarding Successful Completion Of Unannounced USFDA Onsite Bioequivalence Inspection.
Successful completion of unannounced USFDA onsite inspection at Alembic Pharmaceuticals Limited's Bioequivalence Facility in Vadodara, Gujarat.
Company Update / General View filing →
-
7 September 2026 ·
Intimation Under Regulation 30 Of SEBI LODR Regulations, 2015 - Inc orporation Of A Wholly Owned Subsidiary Company
Please find enclosed herewith the Intimation regarding Inc orporation of a wholly owned subsidiary company of the Company.
Company Update / General View filing →
-
27 August 2026 ·
Analyst / Investor Meet - Intimation
Please find attached.
Company Update / Analyst / Investor Meet View filing →
-
27 August 2026 ·
Analyst / Investor Meet - Intimation
Please find attached.
Company Update / Analyst / Investor Meet View filing →
-
25 August 2026 ·
-
20 August 2026 ·
Appointment of Company Secretary and Compliance Officer
Intimation regarding Appointment of Company Secretary of the Company.
Company Update / Appointment of Company Secretary / Compliance Officer View filing →
-
11 August 2026 ·
-
10 August 2026 ·
Resignation of Company Secretary / Compliance Officer
Please find attached.
Company Update / Resignation of Company Secretary / Compliance Officer View filing →
-
10 August 2026 ·
Earnings Call Transcript
Please find attached herewith the Transcript of Post Result Conference Call held on 4th August, 2026.
Company Update / Earnings Call Transcript View filing →
-
6 August 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
Please find attached herewith the Scrutinizer Report and Voting Results of the AGM held on 5th August, 2026.
AGM/EGM / AGM View filing →
-
5 August 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Please find attached Proceedings of AGM held on 5th August, 2026.
AGM/EGM / AGM View filing →
-
5 August 2026 ·
Newspaper Publication
Please find attached herewith the Newspaper Advertisement.
Company Update / Newspaper Publication View filing →
-
4 August 2026 ·
Analyst / Investor Meet - Outcome
Please find attached audio recording of investor call.
Company Update / Analyst / Investor Meet View filing →
-
4 August 2026 ·
Press Release / Media Release (Revised)
Please find attached Revised Press Release on Unaudited Financial Results for the quarter ended 30th June, 2026.
Company Update / Press Release / Media Release (Revised) View filing →
-
4 August 2026 ·
Press Release / Media Release
Please find attached Press Release on Unaudited Financial Results for the quarter ended 30th June, 2026.
Company Update / Press Release / Media Release View filing →
-
4 August 2026 ·
Investor Presentation
Please find attached Investor Presentation.
Company Update / Investor Presentation View filing →
-
4 August 2026 ·
Unaudited Financial Results For The Quarter Ended June 30, 2026
Please find attached Unaudited Financial Results for the Quarter ended 30th June, 2026.
Result / Financial Results View filing →
-
4 August 2026 ·
Board Meeting Outcome for Outcome Of Board Meeting
Please find enclosed herewith Outcome of Board Meeting.
Board Meeting / Outcome of Board Meeting View filing →
-
28 July 2026 ·
Press Release / Media Release
Alembic Pharmaceuticals Limited receives USFDA Final approval for Prucalopride Tablets, 1 mg and 2 mg.
Company Update / Press Release / Media Release View filing →
-
27 July 2026 ·
Analyst / Investor Meet - Intimation
Please find attached herewith Intimation for Investors Call Scheduled to be held on 4th August, 2026.
Company Update / Analyst / Investor Meet View filing →
-
24 July 2026 ·
Board Meeting Intimation for Board Meeting To Consider Unaudited Financial Results For The Quarter Ended 30Th June, 2026.
Alembic Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2026 ,inter alia, to consider and approve Unaudited Financial ....
Board Meeting / Board Meeting View filing →
RSS feed for Alembic Pharmaceuticals Ltd · the 50 most recent filings